#ACC21 – [Not published yet] RCT: Among patients undergoing TAVR, full-dose apixaban is not superior to standard of care (vitamin K antagonist if indication for oral anticoagulation; antiplatelet therapy if no indication).

Anti-Thrombotic Strategy to Lower All cardiovascular and Neurologic Ischemic and Hemorrhagic Events after Trans-Aortic Valve Implantation for Aortic Stenosis – ATLANTIS – American College of Cardiology

Commentaries: ATLANTIS: Apixaban Not Superior to Standard Care After TAVR – American College of Cardiology AND ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI – TCTMD